Koers BioLineRX Ltd. TEL AVIV STOCK EXCHANGE
Aandelen
IL0011015182
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 14,36 mln. 5,47 mld. 13,44 mln. | Omzet 2025 * | 27,77 mln. 10,57 mld. 25,97 mln. | Marktkapitalisatie | 52,63 mln. 20,04 mld. 49,22 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -47 mln. -17,89 mld. -43,96 mln. | Nettowinst (verlies) 2025 * | -36 mln. -13,71 mld. -33,67 mln. | EV/omzet 2024 * | 3,66 x |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | 1,9 x |
K/w-verhouding 2024 * |
-2,19
x | K/w-verhouding 2025 * |
-
| Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 99,64% |
Recentste transcriptie over BioLineRX Ltd.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Philip Serlin
CEO | Chief Executive Officer | 62 | 24-05-09 |
Mali Zeevi
DFI | Director of Finance/CFO | 48 | 01-01-09 |
Irit Gliko-Kabir
CTO | Chief Tech/Sci/R&D Officer | - | 01-09-17 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Sandra Panem
BRD | Director/Board Member | 77 | 24-02-14 |
Avraham Molcho
BRD | Director/Board Member | 66 | 01-01-10 |
Aharon Schwartz
CHM | Chairman | 80 | 01-01-04 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-2,31% | 103 mld. | |
+0,56% | 95,28 mld. | |
+1,69% | 22,15 mld. | |
-17,37% | 21,02 mld. | |
-9,30% | 18,15 mld. | |
-41,01% | 16,74 mld. | |
-14,85% | 16,05 mld. | |
+3,21% | 13,68 mld. | |
+33,54% | 12,17 mld. |